Extensive Lentigo Maligna Clearing With Topical Imiquimod

Viral and Nonviral Uses of Imiquimod: A Review

“…57 Four separate case studies observed clearance of LM after application of imiquimod cream. [58][59][60][61] In 2003, Naylor et al 62 conducted a trial with 30 subjects who applied imiquimod daily for 3 months. At the end of the 3 months, 28 of the subjects had completed the treatment phase and 26 (93%) were complete responders.…”

A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance

“…Clearance rates varied from 100% in early case reports and small case series to the 60% to 80% range in later larger cohort studies. [14][15][16][17] There is only 1 randomized controlled trial that found no statistically significant difference in histologic clearance rates produced by imiquimod monotherapy and imiquimod and tazorac combination therapy for LM (64% vs 78% [P \ .05]). 18 Existing studies have a wide variation in reported treatment protocols, the assessment of outcomes, and duration of follow-up, making it challenging to reach a consensus regarding the optimal treatment regimen.…”

Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy

“…1,[29][30][31][32][33] Imiquimod is a topical immune-response modifier which enhances both innate and acquired immunity. When administered orally or topically, it stimulates rapid synthesis and release of cytokines (particularly interferon alfa [IFN-␣], IFN-␥, and interleukin-12) from monocytes, macrophages, dendritic cells, and keratinocytes via activation of Toll-like receptor 7 and up-regulation of the transcription factor NF-B.…”